Hill Country Eye Center Blog

Patients of age-related macular degeneration may soon have reason to celebrate.

The Food and Drug Administration has approved a new form of treatment called Eylea or VEGF Trap-Eye.

Currently, individuals with the potentially blinding disease have been forced to report to the eye doctor office monthly to receive injections for treatment of the condition.

This new product may significantly reduce the number of trips required to see the same results.

After two studies, involving approximately 2,500 participants, it has been made clear that Eylea can provide the same efficacy expected of current treatment, but patients, will receive injections for two months straight and then can spread the visits out to every eight weeks.

This, of course, will mean that patients will spend less time and money at the doctor’s office, while seeing the same results that they have come to expect.

The ophthalmology community is very excited about the prospect and those involved in the study have said that Eylea should be available right away.

Though the risks of treatment remain the same as those of the more traditional injections – including eye pain, conjunctival hemorrhage, and vitreous floaters – the discomfort associated with treatment will be far less frequent, which is a relief for many wet AMD sufferers.

To read more about these studies and the FDA’s decision, you can view the full article here.